Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6784248 | 0.85 | MTNR1A (0.44) | SLC6A4HRH3MEN1KMT2ADRD2 | |
| SCHEMBL6789308 | 0.84 | DRD2 (0.58) | MEN1KMT2ADRD2 | |
| SCHEMBL6720905 | 0.81 | SLC6A4 (0.54) | SLC6A4HRH3MEN1KMT2ADRD2 | |
| SCHEMBL7094962 | 0.78 | MAPT (0.56) | SLC6A4MEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL27509223 | 0.77 | MAPT (0.55) | SLC6A4MEN1KMT2A | |
| SCHEMBL6710735 | 0.76 | SLC6A4 (0.68) | SLC6A4HRH3MEN1KMT2ADRD2 | |
| SCHEMBL6529308 | 0.75 | SLC6A4 (0.46) | SLC6A4MEN1KMT2A | |
| SCHEMBL6784657 | 0.75 | SLC6A4 (0.57) | SLC6A4HRH3DRD2 | |
| SCHEMBL8043711 | 0.74 | DRD2 (0.61) | SLC6A4MEN1KMT2ACHRM2CHRM4 | |
| SCHEMBL8043716 | 0.74 | DRD2 (0.61) | SLC6A4MEN1KMT2ACHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | BOUILLOT ANNE (FR) | 2004-07-29 | — | — | US | disclosed |
| EP-1351937-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002055497-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | NR1H2, NR1H3, NR1H4 | SLC6A4 969/4885HRH3 423/4885MEN1 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.